- One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to Bank of America analysts.
- The analysts say companies such as Illumina and Alphabet are on the cusp of “bringing unprecedented increases to the quality and length of human lifespans.”
- The Bank of America team highlights five key sub-themes, as well as several stocks with exposure to the trend.
One of the biggest investment opportunities over the next decade will be in companies working to delay human death, a market expected to be worth at least $600 billion by 2025, according to one of Wall Street’s major investment banks.
Bank of America Merrill Lynch analysts Felix Tran and Haim Israel believe that genome sequencers such as Illumina, high-tech players such as Alphabet and biotech companies such as Novartis are on the cusp of “bringing unprecedented increases to the quality and length of human lifespans.”
Innovation in genome science, big data and “ammortality,” which includes wearable technology and products in the so-called wellness space, could soon prolong healthy human life well beyond 100 years, BofA told clients Wednesday.
www.cnbc.com/2019/05/08/techs-next-big-disruption-could-be-delaying-death.html